Merck has voluntarily withdrawn its European approval application for Lagevrio, an oral COVID-19 treatment. The pharmaceutical industry is paying close attention to whether the global supply of this drug will continue. Celltrion and Hanmi Pharmaceutical, which had already decided to produce and supply Lagevrio generics to developing countries, have withdrawn their plans. Foreign media including Reuters reported on the 28th (local time) that Merck voluntarily withdrew its application for permission from the European Union (EU) for Lagevrio, an oral COVID-19 treatment. It is an analysis that Europe is in fact stepping out of the process. The EMA-affiliated CHMP recommended banning Lagevrio approval in February this yea